Duetact is a brand name of glimepiride/pioglitazone, approved by the FDA in the following formulation(s):
DUETACT (glimepiride; pioglitazone hydrochloride - tablet; oral)
Manufacturer: TAKEDA GLOBAL
Approval date: July 28, 2006
Strength(s): 2MG;30MG [RLD], 4MG;30MG
Has a generic version of Duetact been approved?
No. There is currently no therapeutically equivalent version of Duetact available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Duetact. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Pharmaceutical composition
Patent 6,150,383
Issued: November 21, 2000
Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
Assignee(s): Takeda Chemical Industries, Ltd.
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.Patent expiration dates:
- June 19, 2016✓
- June 19, 2016
Pharmaceutical composition
Patent 6,211,205
Issued: April 3, 2001
Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
Assignee(s): Takeda Chemical Industries, Ltd.
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.Patent expiration dates:
- June 19, 2016✓
- June 19, 2016
Pharmaceutical composition
Patent 6,303,640
Issued: October 16, 2001
Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
Assignee(s): Takeda Chemical Industries, Ltd.
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.Patent expiration dates:
- August 9, 2016✓
- August 9, 2016
Pharmaceutical composition
Patent 6,329,404
Issued: December 11, 2001
Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
Assignee(s): Takeda Chemical Industries, Ltd.
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.Patent expiration dates:
- June 19, 2016✓✓
- June 19, 2016
Pharmaceutical composition
Patent 7,538,125
Issued: May 26, 2009
Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
Assignee(s): Takeda Pharmaceutical Company Limited
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.Patent expiration dates:
- June 19, 2016✓
- June 19, 2016
Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
Patent 7,700,128
Issued: April 20, 2010
Inventor(s): Doken; Kazuhiro & Kawano; Tetsuya & Koyama; Hiroyoshi & Hamaguchi; Naoru
Assignee(s): Takeda Pharmaceutical Company Limited
A solid preparation useful as a diabetes-treating agent or the like and excellent in the dissolution properties of an insulin sensitizer and an insulin secretagogue, which comprises an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester is provided.Patent expiration dates:
- January 30, 2027✓
- January 30, 2027
Solid preparation
Patent 8,071,130
Issued: December 6, 2011
Inventor(s): Kiyoshima; Kenichiro & Nakamura; Kenji & Kawano; Tetsuya & Misaki; Masafumi
Assignee(s): Takeda Pharmaceutical Company Limited
The present invention intends to provide a solid preparation which contains an insulin sensitizer and an active ingredient other than an insulin sensitizer, and exhibits dissolution behavior of an insulin sensitizer similar to that of an insulin sensitizer from “a solid preparation containing only an insulin sensitizer as an active ingredient”. The solid preparation comprises “a part containing coated particles in which the particles containing an insulin sensitizer are coated with lactose or a sugar alcohol” and “a part containing an active ingredient other than an insulin sensitizer”.Patent expiration dates:
- June 8, 2028✓
- June 8, 2028
See also...
- Duetact Consumer Information (Drugs.com)
- Duetact Consumer Information (Wolters Kluwer)
- Duetact Consumer Information (Cerner Multum)
- Duetact Advanced Consumer Information (Micromedex)
- Glimepiride/Pioglitazone Consumer Information (Wolters Kluwer)
- Pioglitazone/Glimepiride Consumer Information (Wolters Kluwer)
- Glimepiride and pioglitazone Consumer Information (Cerner Multum)
- Pioglitazone and glimepiride Advanced Consumer Information (Micromedex)
No comments:
Post a Comment